Ercanetide clinical trials
Also written NNZ-2591.
How each study uses ercanetide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ercanetide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Neuren Pharmaceuticals Limited (7)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test ercanetide, phase 3 first.
- Oct 2027A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromePhase 3 · Neuren Pharmaceuticals Limited
Studies
Open first, then newest update. How each study uses ercanetide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeRecruitingPhase 3Neuren Pharmaceuticals LimitedNCT07593391Written as NNZ-2591
- A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeRecruitingPhase 3Neuren Pharmaceuticals LimitedNCT07281079Written as NNZ-2591
- An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)CompletedPhase 2Neuren Pharmaceuticals LimitedNCT05025332Written as NNZ-2591
- An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)CompletedPhase 2Neuren Pharmaceuticals LimitedNCT05025241Written as NNZ-2591
- An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT05011851Written as NNZ-2591
- An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)WithdrawnPhase 2Neuren Pharmaceuticals LimitedNCT05879614Written as NNZ-2591
- To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy VolunteersCompletedPhase 1Neuren Pharmaceuticals LimitedNCT04379869Written as NNZ-2591
Codes
What other systems call ercanetide · ClinicalTrials.gg INT005423
- UNII (FDA) 2T1HU6069SERCANETIDEConfirmed FDA, Wikidata
- Wikidata Q27255561ercanetideConfirmed FDA, Wikidata
- NCI Thesaurus C224738ErcanetideOne source FDA
- DrugBank DB15601One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2T1HU6069S | ERCANETIDE | Confirmed FDA, Wikidata |
| Wikidata | Q27255561 | ercanetide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C224738 | Ercanetide | One source FDA |
| DrugBank | DB15601 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.